Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 147 | 44 | 102 |
| Samples | 140 | 44 | 95 |
| Peptides | 106 | 29 | 79 |
Function
HLA-DMB · Major histocompatibility complex, class II, DM beta
HLA-DMB belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DMA) and a beta (DMB) chain, both anchored in the membrane. It is located in intracellular vesicles. DM plays a central role in the peptide loading of MHC class II molecules by helping to release the CLIP (class II-associated invariant chain peptide) molecule from the peptide binding site. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000418107 | P28068 | 147 | 106 |
Gene Properties
Recurrent Mutations
All 106 amino-acid changes on canonical ENST00000418107 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HLA-DMB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HLA-DMB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 3/210 1% | 23/1899 1% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Other Solid Cancers | 0/94 0% | 9/1515 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 0/810 0% |
| Endometrial Carcinoma | 1/42 2% | 2/612 0% |
| Colorectal Carcinoma | 4/143 3% | 11/3239 0% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 3/2534 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Glioma | 1/52 2% | 5/2127 0% |
| Prostate Carcinoma | 2/13 15% | 4/2105 0% |
| Ovarian Carcinoma | 3/109 3% | 0/998 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Other Blood Cancers | 2/61 3% | 5/2725 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 3/1390 0% |
| Head and Neck Carcinoma | 2/85 2% | 2/1574 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
| Breast Carcinoma | 1/144 1% | 4/3264 0% |
| Kidney Carcinoma | 1/85 1% | 2/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 1/2550 0% |
| Hepatocellular Carcinoma | 0/46 0% | 1/2210 0% |
Mutation Distribution
Where HLA-DMB is mutated · all tissues, split by cell line vs tissue
How many mutations in HLA-DMB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 147 mutations in HLA-DMB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|